Identification of Six Serum Antigens and Autoantibodies for the Detection of Early Stage Epithelial Ovarian Carcinoma by Bioinformatics Analysis and Liquid Chip Analysis

Overview

Journal Oncol Lett

Specialty Oncology

Date 2018 Aug 22

PMID 30127919

Citations 2

Authors

Yupeng Zou

Li Li

Affiliations

Soon will be listed here.

Abstract

The early detection of ovarian cancer is critical for improving the prognosis of patients, but there are currently insufficient tumor biomarkers for early detection owing to their low diagnostic sensitivity and specificity. The aim of the present study was to investigate the use of the serum antigens C-C motif chemokine ligand 18 and C-X-C motif chemokine ligand 1, and autoantibodies C1D, transmembrane 4 L six family member 1, zinc finger protein 675 and fragile X mental retardation 1 autosomal homolog 1, for the early screening of epithelial ovarian cancer (EOC). The expression of these sex genes/proteins in ovarian cancer and normal ovarian tissue was examined, and the potential functions of the six genes/proteins in ovarian cancer were analyzed by bioinformatics. Finally, these data were verified in clinical samples, and the multi-analyte suspension array method was compared with the ELISA method. Taken together, these data indicated that these six genes/proteins may serve as potential biomarkers for the early detection of EOC.

Citing Articles

A combined biomarker panel shows improved sensitivity and specificity for detection of ovarian cancer.

Mao L, Tang Y, Deng M, Huang C, Lan D, Nong W J Clin Lab Anal. 2022; 36(2):e24232.

PMID: 34995016 PMC: 8842139. DOI: 10.1002/jcla.24232.

Anti-Cancer Auto-Antibodies: Roles, Applications and Open Issues.

de Jonge H, Iamele L, Maggi M, Pessino G, Scotti C Cancers (Basel). 2021; 13(4).

PMID: 33672007 PMC: 7919283. DOI: 10.3390/cancers13040813.

References

Capriglione S, Luvero D, Plotti F, Terranova C, Montera R, Scaletta G . Ovarian cancer recurrence and early detection: may HE4 play a key role in this open challenge? A systematic review of literature. Med Oncol. 2017; 34(9):164. DOI: 10.1007/s12032-017-1026-y. View

Sopik V, Iqbal J, Rosen B, Narod S . Why have ovarian cancer mortality rates declined? Part II. Case-fatality. Gynecol Oncol. 2015; 138(3):750-6. DOI: 10.1016/j.ygyno.2015.06.016. View

Raheja R, Gandhi R . FXR1: Linking cellular quiescence, immune genes and cancer. Cell Cycle. 2016; 15(20):2695-6. PMC: 5053567. DOI: 10.1080/15384101.2016.1215692. View

Siegel R, Miller K, Jemal A . Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30. DOI: 10.3322/caac.21387. View

Wani N, Nasser M, Ahirwar D, Zhao H, Miao Z, Shilo K . C-X-C motif chemokine 12/C-X-C chemokine receptor type 7 signaling regulates breast cancer growth and metastasis by modulating the tumor microenvironment. Breast Cancer Res. 2014; 16(3):R54. PMC: 4076630. DOI: 10.1186/bcr3665. View

Wang Q, Zhang W, Li D, Li L . [Identification of two potential serum biomarkers for ovarian cancer and clinical validation thereof]. Zhonghua Yi Xue Za Zhi. 2008; 88(15):1012-6. View

Wang Q, Tang Y, Yu H, Yin Q, Li M, Shi L . CCL18 from tumor-cells promotes epithelial ovarian cancer metastasis via mTOR signaling pathway. Mol Carcinog. 2015; 55(11):1688-1699. PMC: 5057350. DOI: 10.1002/mc.22419. View

Schutyser E, Struyf S, Proost P, Opdenakker G, Laureys G, Verhasselt B . Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma. J Biol Chem. 2002; 277(27):24584-93. DOI: 10.1074/jbc.M112275200. View

Qian J, Hassanein M, Hoeksema M, Harris B, Zou Y, Chen H . The RNA binding protein FXR1 is a new driver in the 3q26-29 amplicon and predicts poor prognosis in human cancers. Proc Natl Acad Sci U S A. 2015; 112(11):3469-74. PMC: 4371932. DOI: 10.1073/pnas.1421975112. View

10.

Abu Hassan S, Nielsen D, Tuxen M, Petersen P, Soletormos G . Performance of seven criteria to assess CA125 increments among ovarian cancer patients monitored during first-line chemotherapy and the post-therapy follow-up period. Future Sci OA. 2017; 3(3):FSO216. PMC: 5583662. DOI: 10.4155/fsoa-2017-0023. View

11.

Yuan S, Qiao T, Qiang J, Cai S, Li R . The value of DCE-MRI in assessing histopathological and molecular biological features in induced rat epithelial ovarian carcinomas. J Ovarian Res. 2017; 10(1):65. PMC: 5615469. DOI: 10.1186/s13048-017-0362-z. View

12.

Li G, Liu J, Abu-Asab M, Masabumi S, Maru Y . XPB induces C1D expression to counteract UV-induced apoptosis. Mol Cancer Res. 2010; 8(6):885-95. PMC: 2895254. DOI: 10.1158/1541-7786.MCR-09-0467. View

13.

Kandukuri S, Rao J . FIGO 2013 staging system for ovarian cancer: what is new in comparison to the 1988 staging system?. Curr Opin Obstet Gynecol. 2014; 27(1):48-52. DOI: 10.1097/GCO.0000000000000135. View

14.

Huang Y, Fan X, Qiu F . TM4SF1 Promotes Proliferation, Invasion, and Metastasis in Human Liver Cancer Cells. Int J Mol Sci. 2016; 17(5). PMC: 4881487. DOI: 10.3390/ijms17050661. View

15.

Yang Z, Yang G, Jiang Y, Ran Y, Yang Z, Zhang W . [Screening and sero-immunoscreening of ovarian epithelial cancer associative antigens]. Zhonghua Fu Chan Ke Za Zhi. 2008; 42(12):834-9. View

16.

Jackson R, Wu J, Chen E . C1D family proteins in coordinating RNA processing, chromosome condensation and DNA damage response. Cell Div. 2016; 11:2. PMC: 4812661. DOI: 10.1186/s13008-016-0014-5. View

17.

Park Y, Lee S, Kim S, Liu Y, Lee M, Shin J . MicroRNA-9 suppresses cell migration and invasion through downregulation of TM4SF1 in colorectal cancer. Int J Oncol. 2016; 48(5):2135-43. DOI: 10.3892/ijo.2016.3430. View

18.

Li H, Cui X, Wu W, Yu F, Yao H, Liu Q . Pyk2 and Src mediate signaling to CCL18-induced breast cancer metastasis. J Cell Biochem. 2013; 115(3):596-603. DOI: 10.1002/jcb.24697. View

19.

Jo Y, Kim S, Kim M, Yoo N, Lee S . Frameshift Mutation of FXR1 Encoding a RNA-Binding Protein in Gastric and Colorectal Cancers with Microsatellite Instability. Pathol Oncol Res. 2016; 23(2):453-454. DOI: 10.1007/s12253-016-0177-z. View

20.

Goff B, Agnew K, Neradilek M, Gray H, Liao J, Urban R . Combining a symptom index, CA125 and HE4 (triple screen) to detect ovarian cancer in women with a pelvic mass. Gynecol Oncol. 2017; 147(2):291-295. DOI: 10.1016/j.ygyno.2017.08.020. View